VokonasPSKannelWB. Diabetes mellitus and coronary heart disease in the elderly. Clin Geriatr Med1996;12: 69–78.
2.
SHEP Cooperative Research Group. Implications of the systolic hypertension in the elderly program. The systolic hypertension in the elderly program (SHEP). JAMA1991;265: 3255–64.
3.
GrossmanEMesserliFH. Diabetic and hypertensive heart disease. Ann Intern Med1996;125: 304–10.
4.
Fernandez-BrittoJEBacallaoJCastilloJACamposRWongRGuskiH. Atherosclerosis in diabetes and hypertension. A comparative morphometric study of their progression using an atherometric system. Zentralbl Pathol1991;137: 487–91.
5.
National High Blood Pressure Education Program Working Group. National high blood pressure education program working group on hypertension in diabetes. Hypertension1994;23:145–58.
6.
EpsteinM. Diabetes and hypertension: The bad companions. J Hypertension1997;15 (suppl 2):S55–62.
7.
SaltielAROlefskyJM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes1996;45: 1661–9.
8.
KumarSBoultonAJMBeck-NielsenHBerthezeneFMaggeoMPerssonBTroglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia1996;39:701–9.
9.
GhazziMNPerezJEAntonucciTKDriscollJHHuangSMFajaBWCardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes1997;46:433–9.
10.
SironiAMVichiSGastaldelliAPecoriNAnichiniRFootEEffects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin dependent diabetes. Clin Pharmacol Ther1997;62:194–202.
11.
OgiharaTRakugiHIdegamiHMikamiHMasuoK. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens1995;8: 316–20.
12.
NagasakaYKakuKNakamuraKKanekoT. The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro. Biochem Pharmacol1995;50: 1109–11.
13.
NoguchiNSakaiHKatoYTsuchiyaJYamamotoYNikiEInhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis1996;123:227–34.
14.
CominaciniLGarbinUPasiniAFCampagnolaMDavoliAFootETroglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes1998;47:130–3.
15.
SteinbergDParthasanathySSCarewTEKhooJCWitztumJL. Beyond cholesterol: Modification of low-density lipoprotein that increases its atherogenicity. N Engl J Med1989;320: 919–24.
16.
JellinJ, ed. Patient testing and labeling strengthened for Rezulin. Pharm Lett1998;13:70.
MeigsJBSingerDESullivanLMDukesKAD'AgostinoRBNathanDMMetabolic control and prevalent cardiovascular disease in non-insulin dependent diabetes mellitus (NIDDM): The NIDDM patient outcomes research team. Am J Med1997;102:38–47.
